Related Experiment Videos
Sickle cell crisis and endothelin antagonists.
Allan D Angerio1, Nicole D Lee
1School of Nursing and Health Studies, Georgetown University, Washington, DC 20057-1107, USA. angerioa@georgetown.edu
Critical Care Nursing Quarterly
|August 22, 2003
Summary
Sickle cell crisis involves more than just vaso-occlusion. Endothelin-1 (ET-1) contributes to sickle cell crisis, suggesting ET-1 antagonists could be effective treatments.
Area of Science:
- Hematology
- Vascular Biology
- Pharmacology
Background:
- Sickle cell crisis is often viewed as a vaso-occlusive event.
- Hypoxia triggers the release of Endothelin-1 (ET-1), a potent vasoconstrictor.
Purpose of the Study:
- To investigate the role of Endothelin-1 (ET-1) in the pathophysiology of sickle cell crisis.
- To explore the potential therapeutic benefits of ET-1 antagonists in sickle cell crisis.
Main Methods:
- Review of existing literature on sickle cell disease pathophysiology.
- Analysis of the known effects of Endothelin-1 (ET-1) in vascular and inflammatory processes.
Main Results:
- Endothelin-1 (ET-1) is implicated in promoting vaso-occlusion and inflammation during sickle cell crisis.
- ET-1's vasoconstrictive and mitogenic properties contribute to the complex pathology.
Conclusions:
- Sickle cell crisis pathophysiology is complex and involves factors beyond simple vaso-occlusion.
- Endothelin-1 (ET-1) antagonists show promise for preventing and treating sickle cell crisis.